Hay fever makes the summer miserable for so many people, and the possibilities for treatment are daily antihistamines, or allergy shots, low doses of an extract of pollen under the skin for as long as 5 years. Biomay is developing a recombinant grass pollen allergy vaccine, known as BM32, that could cut symptoms after just three doses. The vaccine has just started a Phase II trial in Vienna, where 60 patients will get three doses, and the researchers are looking for a fall in symptoms, as well as indications for the dose for larger clinical trials. This is the first of Biomay's peptide-carrier vaccines, made up of an antigen fused to a carrier peptide, and if the results are positive, the company will use the technology to develop vaccines against other allergies. Article